Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translatio... von André, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J-B., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., Aissat, N., Cayre, A., Penault-Llorca, F., Laurent-Puig, P., de Gramont, A.

Volltext

CPT-11 (Irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer von André, T, Louvet, C, Maindrault-Goebel, F, Couteau, C, Mabro, M, Lotz, J.P, Gilles-Amar, V, Krulik, M, Carola, E, Izrael, V, de Gramont, A

Volltext

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with... von Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., Taieb, J., Brucker, P., Landi, B., Flesch, M., Carola, E., Martin, P., Vaillant, E., de Gramont, A.

Volltext

Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly von APARICIO, T, DESRAME, J, ARTRU, P, MABRO, M, DOMINGUEZ, S, AGEO, For, LECOMTE, T, MITRY, E, BELLOC, J, ETIENNEY, I, MONTEMBAULT, S, VAYRE, L, LOCHER, C, EZENFIS, J

Volltext

FOLFOX4 versus sequential dose-dense FOLFOX7 followed by FOLFIRI in patients with resectable metastatic colorectal cancer (MIROX): a pragmatic approach to chemotherapy timing with... von Hebbar, M., Chibaudel, B., André, T., Mineur, L., Smith, D., Louvet, C., Dutel, J.L., Ychou, M., Legoux, J.L., Mabro, M., Faroux, R., Auby, D., Brusquant, D., Khalil, A., Truant, S., Hadengue, A., Dalban, C., Gayet, B., Paye, F., Pruvot, F.R., Bonnetain, F., de Gramont, A.

Volltext

A phase II study of FOLFIRI-3 (double infusion of irinotecan combined with LV5FU) after FOLFOX in advanced colorectal cancer patients von MABRO, M, ARTRU, P, ANDRE, T, FLESCH, M, MAINDRAULT-GOEBEL, F, LANDI, B, LLEDO, G, PLANTADE, A, LOUVET, C, DE GRAMONT, A

Volltext

Efficacy of FOLFIRI-3 (irinotecan D1,D3 combined with LV5-FU) or other irinotecan-based regimens in oxaliplatin-pretreated metastatic colorectal cancer in the GERCOR OPTIMOX1 study von Bidard, F.-C., Tournigand, C., André, T., Mabro, M., Figer, A., Cervantes, A., Lledo, G., Bengrine-Lefevre, L., Maindrault-Goebel, F., Louvet, C., de Gramont, A.

Volltext

Oxaliplatin reintroduction in patients previously treated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer von Maindrault-Gœbel, F., Tournigand, C., André, T., Carola, E., Mabro, M., Artru, P., Louvet, C., de Gramont, A.

Volltext

Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer von Maindrault-Gæbel, F., de Gramont, A., Louvet, C., André, T., Carola, E., Gilles, V., Lotz, J.-P., Tournigand, C., Mabro, M., Molitor, J.-L., Artru, P., Izrael, V., Krulik, M.

Volltext

Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study von André, T., Tournigand, C., Mineur, L., Fellague-Chebra, R., Flesch, M., Mabro, M., Hebbar, M., Postel Vinay, S., Bidard, F.C., Louvet, C., de Gramont, A.

Volltext

High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7) von Maindrault-Gœbel, F, de Gramont, A, Louvet, C, André, T, Carola, E, Mabro, M, Artru, P, Gilles, V, Lotz, J.P, Izrael, V, Krulik, M

Volltext

Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial von Bennouna, Jaafar, MD, Sastre, Javier, MD, Arnold, Dirk, Prof, Österlund, Pia, MD, Greil, Richard, Prof, Van Cutsem, Eric, Prof, von Moos, Roger, MD, Viéitez, Jose Maria, MD, Bouché, Olivier, Prof, Borg, Christophe, MD, Steffens, Claus-Christoph, MD, Alonso-Orduña, Vicente, MD, Schlichting, Christoph, MD, Reyes-Rivera, Irmarie, MD, Bendahmane, Belguendouz, MD, André, Thierry, Prof, Kubicka, Stefan, Prof

Volltext

6144 POSTER Phase II Study of Panitumumab With Irinotecan for Patients With KRas Wild-type Metastatic Colorectal Cancer (MCRC) Refractory to Standard Chemotherapy – a GERCor Study... von Andre, T, Chibaudel, B, Mabro, M, Bennamoun, M, Artru, P, Bachet, J.B, Hadengue, A, Blons, H, Laurent-Puig, P, de Gramont, A

Volltext

1204MO PRODIGE 59 - DURIGAST trial: A randomised phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patient... von Tougeron, D., Dahan, L., El Hajbi, F., Le Malicot, K., Evesque, L., Aparicio, T., Bouche, O., Bonichon Lamichhane, N., Chibaudel, B., Angelergues, A., A. bodere, Phelip, J.M., Mabro, M., Artru, P., Louvet, C.

Volltext

Randomized phase III trial in elderly patients comparing LV5FU2 with or without irinotecan for first-line treatment of metastatic colorectal cancer (FFCD 2001–02) von Aparicio, T., Lavau-Denes, S., Phelip, J.M., Maillard, E., Jouve, J.L., Gargot, D., Gasmi, M., Locher, C., Adhoute, X., Michel, P., Khemissa, F., Lecomte, T., Provençal, J., Breysacher, G., Legoux, J.L., Lepère, C., Charneau, J., Cretin, J., Chone, L., Azzedine, A., Bouché, O., Sobhani, I., Bedenne, L., Mitry, E., Amoyal, P., Auby, D., Bachet, J.B., Baconnier, M., Benoit, R., Berthelet, O., Bidault, A., Bineau, C., Bordes, G., Bouarioua, N., Boucher, E., Boulat, O., Cleau, D., Couzigou, P., Cuillerier, E., Cumin, I., Denis, B., Di Fiore, F., Derias, V., Ezenfis, J., Faroux, R., Gagnaire, A., Gatineau-Sailliant, G., Garcia, B., Genet, D., Gueye, A., Hammel, P., Lagasse, J.P., Landi, B., Lepage, C., Lobry, C., Lombard-Bohas, C., Mabro, M., Mackiewicz, R., Martin, J., Moncoucy, X., Morvan, F., Mozer, M., Pauwels, M., Petit-Laurent, F., Pouderoux, P., Prost, P., Queuniet, A.M., Ramdani, M., Rebischung, C., Rougier, P., Schnee, M., Seitz, J.F., Stefani, L., Taïeb, J., Terrebonne, E., Texereau, P., Thaury, J., Tougeron, D., Weber, A., Ricard, F., Bonnetain, F., Masskouri, F., Choine, C., Guiliani, F., Le Pessec, G., Fattouh, H., Le Provost, N., Girault, C., Schneider, M.

Volltext

Phase II Study of Biweekly Pemetrexed Plus Irinotecan as Second-Line Therapy for Metastatic Colorectal Cancer von Louvet, C., André, T., Gamelin, Erick, Hebbar, M., Mabro, M., Bennamoun, M., Rassam, H., de Gramont, A.

Volltext

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study... von Kubicka, S., André, T., von Moos, R., Österlund, P., Reyes-Rivera, I., Müller, T., Arnold, D., Balcke, P., Benedicic, B., Eisterer, W., Fridrik, M., Samonigg, H., Arts, J., De Man, M., Janssens, J., Benczikova, B., Prausova, J., Vitek, P., Jensen, B.B., Keldsen, N., Østerlind, K., Borg, C., Breysacher, G., Chone, L., Dourthe, L.-M., Faroux, R., Illory, J.F., Lecomte, T., Legoux, J.-L., Levache, B., Lotz, J.-P., Mabro, M., Manfredi, S., Matysiak Budnik, T., Miglianico, L., Pezet, D., Porneuf, M., Tournigand, C., Viret, F., Ychou, M., Bangerter, M., Bertram, M.E., Bohnsteen, B., Cordes, H.-J., Eggert, J., Engel, E., Florschütz, A., Freier, W., Freund, M., Göhler, T., Hagen, V., Hebart, H.F., Heike, M., Höffkes, H.-G., Kettner, E., Kneba, M., Kojouharoff, G., Kretzschmar, A., Kröning, H., Lammert, F., Papke, J., Rädle, J., Ridwelski, K., Rudi, J., Schmalenberger, A., Schwarzer, A., Schwerdtfeger, M., Selbach, J., Staib, P., Stauch, M., Steffens, C.-C., Stübs, P., Tischendorf, J., Tummes, D., Von Wichert, G.P.L., Zomorodbaksch, B., Bloemendal, H.J., Guren, T., Soerbye, H., Fragoso, R., Mellidez, J.C., Darwish, T., Aparicio, J., Aranda, E., Camara, J.C., Donnay, O., Escudero, P., Gallego Plazas, J., Gonzalez Flores, E., Gravalos, C., Guardeno, R., Juárez, A., Massuti Sureda, B., Tobena, M., Toral, J.C., Valenti, V., Berglund, A., Fernebro, E., Hess-Umbricht, V., Popescu, R.

Volltext

LBA30_PR - Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration von Taieb, J., Taly, V., Vernerey, D., Bourreau, C., Bennouna, J., Faroux, R., Desrame, J., Bouche, O., Borg, C., Egreteau, J., Mineur, L., Lepere, C., Deplanque, G., Mulot, C., Louvet, C., Mabro, M., Ychou, M., de Gramont, A., Andre, T., Laurent-Puig, P.

Volltext

Analysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration von Taieb, J., Taly, V., Vernerey, D., Bourreau, C., Bennouna, J., Faroux, R., Desrame, J., Bouche, O., Borg, C., Egreteau, J., Mineur, L., Lepere, C., Deplanque, G., Mulot, C., Louvet, C., Mabro, M., Ychou, M., de Gramont, A., Andre, T., Laurent-Puig, P.

Volltext

LBA30_PRAnalysis of circulating tumour DNA (ctDNA) from patients enrolled in the IDEA-FRANCE phase III trial: Prognostic and predictive value for adjuvant treatment duration von Taieb, J, Taly, V, Vernerey, D, Bourreau, C, Bennouna, J, Faroux, R, Desrame, J, Bouche, O, Borg, C, Egreteau, J, Mineur, L, Lepere, C, Deplanque, G, Mulot, C, Louvet, C, Mabro, M, Ychou, M, de Gramont, A, Andre, T, Laurent-Puig, P

Volltext